☰

Jill E. Bargonetti - Publications

Affiliations: 
Biochemistry City University of New York, New York, NY, United States 
Area:
Biochemistry, Molecular Biology, Oncology
Website:
http://biology.hunter.cuny.edu/index.php?option=com_content&view=article&id=73&Itemid=90
Tree Info Similar researchers PubMed Report error

80 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Ellison V, Polotskaia A, Xiao G, Leybengrub P, Qiu W, Lee R, Hendrickson R, Hu W, Bargonetti J. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN. Biorxiv : the Preprint Server For Biology. PMID 38328189 DOI: 10.1101/2024.01.20.576487  0.709
2024 Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, ... ... Bargonetti J, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Letters. 216608. PMID 38199587 DOI: 10.1016/j.canlet.2024.216608  0.649
2023 Rowdo FPM, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, ... ... Bargonetti J, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Biorxiv : the Preprint Server For Biology. PMID 38076873 DOI: 10.1101/2023.06.22.544406  0.65
2022 Canar J, Manandhar-Sasaki P, Bargonetti J. Mutant p53 Together with Gain-of-Function GLP-1/Notch Decreases UVC-Damage-Induced Germline Cell Death but Increases PARP Inhibitor-Induced Germline Cell Death. Cancers. 14. PMID 36230851 DOI: 10.3390/cancers14194929  0.364
2022 Lundine D, Annor GK, Chavez V, Maimos S, Syed Z, Jiang S, Ellison V, Bargonetti J. The C-terminus of gain-of-function mutant p53 R273H is required for association with PARP1 and Poly-ADP-Ribose. Molecular Cancer Research : McR. PMID 36074101 DOI: 10.1158/1541-7786.MCR-22-0133  0.498
2022 Lama R, Xu C, Galster SL, Querol-García J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti J, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, et al. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. Frontiers in Oncology. 12: 933446. PMID 35992795 DOI: 10.3389/fonc.2022.933446  0.44
2021 Annor GK, Elshabassy N, Lundine D, Conde DG, Xiao G, Ellison V, Bargonetti J. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. Frontiers in Cell and Developmental Biology. 9: 772315. PMID 34881245 DOI: 10.3389/fcell.2021.772315  0.589
2021 Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Molecular Pharmaceutics. PMID 34318678 DOI: 10.1021/acs.molpharmaceut.1c00323  0.633
2021 Ellison V, Annor GK, Freedman C, Xiao G, Lundine D, Freulich E, Prives C, Bargonetti J. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget. 12: 1128-1146. PMID 34136083 DOI: 10.18632/oncotarget.27975  0.681
2020 Xiao G, Annor GK, Fung K, Keinänen O, Zeglis BM, Bargonetti J. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics. PMID 33289569 DOI: 10.1021/acs.molpharmaceut.0c00978  0.62
2020 Kim JY, Lee R, Xiao G, Forbes D, Bargonetti J. MDM2-C Functions as an E3 Ubiquitin Ligase. Cancer Management and Research. 12: 7715-7724. PMID 32904724 DOI: 10.2147/Cmar.S260943  0.671
2020 Farooqi K, Ghazvini M, Pride LD, Mazzella L, White D, Pramanik A, Bargonetti J, Moore CW. A Protein in the Yeast Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules. 10. PMID 32156076 DOI: 10.3390/biom10030417  0.43
2019 Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research. PMID 31776133 DOI: 10.1158/0008-5472.Can-19-1036  0.727
2019 Gao C, Xiao G, Bargonetti J. Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget. 10: 5007-5010. PMID 31489110 DOI: 10.18632/Oncotarget.27134  0.662
2019 Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. Journal of Molecular Cell Biology. 11: 605-609. PMID 31283823 DOI: 10.1093/Jmcb/Mjz067  0.44
2019 Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Research : Bcr. 21: 5. PMID 30642351 DOI: 10.1186/S13058-018-1094-8  0.655
2018 Loo LWM, Gao C, Shvetsov YB, Okoro DR, Hernandez BY, Bargonetti J. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Research and Treatment. PMID 30470976 DOI: 10.1007/S10549-018-5065-7  0.461
2018 Gao C, Xiao G, Piersiga A, Gou J, Ogunwobi O, Bargonetti J. Abstract 5188: MDM2 and MDMX promote p53-independent initiation of circulating tumor cells from triple negative breast cancers Cancer Research. 78: 5188-5188. DOI: 10.1158/1538-7445.Am2018-5188  0.707
2017 Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. PMID 28615518 DOI: 10.18632/Oncotarget.18147  0.83
2017 Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, Bargonetti J. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. Npj Breast Cancer. 3. PMID 28232952 DOI: 10.1038/s41523-016-0001-7  0.712
2017 Loo LW, Hernandez BY, Shvetsov Y, Okoro D, Gao C, Bargonetti J. Abstract LB-164: The association between p53, MDM2, and MDM2 isoform C protein expression and survival in a multiethnic population of breast cancer patients Epidemiology. 77. DOI: 10.1158/1538-7445.Am2017-Lb-164  0.45
2017 Qiu W, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson R, Bargonetti J. Abstract 2493: Identification of the mutant p53-PARP-MCM chromatin axis as a triple negative breast cancer replication stress target Cancer Research. 77: 2493-2493. DOI: 10.1158/1538-7445.Am2017-2493  0.711
2016 Qiu W, Polotskaia A, Xiao G, Di L, Philip J, Hendrikson RC, Bargonetti J. Abstract 3684: Proteome-wide triple negative breast cancer mutant p53 association index identifies chromatin unwinding for precision therapeutics Cancer Research. 76: 3684-3684. DOI: 10.1158/1538-7445.Am2016-3684  0.691
2015 Shtraizent N, Matsui H, Polotskaia A, Bargonetti J. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. International Journal of Environmental Research and Public Health. 13. PMID 26703669 DOI: 10.3390/Ijerph13010022  0.464
2015 Rosso M, Polotskaia A, Bargonetti J. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget. 6: 34573-91. PMID 26416444 DOI: 10.18632/Oncotarget.5312  0.519
2015 Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes & Development. 29: 1298-315. PMID 26080815 DOI: 10.1101/Gad.263202.115  0.512
2015 Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proceedings of the National Academy of Sciences of the United States of America. 112: E1220-9. PMID 25733866 DOI: 10.1073/Pnas.1416318112  0.681
2015 Xiao G, Kue P, Bhosle R, Bargonetti J. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle (Georgetown, Tex.). 14: 744-54. PMID 25565400 DOI: 10.1080/15384101.2014.997517  0.741
2015 Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu W, Hendrickson R, Bargonetti J. Abstract 1225: Proteome-wide analysis of gain-of-function mutant p53 targets in breast cancer implicates PARP, PCNA and MCM4 as oncogenic drivers Cancer Research. 75: 1225-1225. DOI: 10.1158/1538-7445.Am2015-1225  0.694
2015 Gao C, Kundu N, Bargonetti J. Abstract 1220: MDM2 promotes p53-independent breast cancer metastatic phenotypes Cancer Research. 75: 1220-1220. DOI: 10.1158/1538-7445.Am2015-1220  0.541
2014 Rosso M, Okoro DE, Bargonetti J. Splice variants of MDM2 in oncogenesis. Sub-Cellular Biochemistry. 85: 247-61. PMID 25201199 DOI: 10.1007/978-94-017-9211-0_14  0.4
2014 Shi M, Shtraizent N, Polotskaia A, Bargonetti J, Matsui H. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure. Plos One. 9: e99351. PMID 24937470 DOI: 10.1371/Journal.Pone.0099351  0.476
2014 Hoffman S, Martin D, Meléndez A, Bargonetti J. C. elegans CEP-1/p53 and BEC-1 are involved in DNA repair. Plos One. 9: e88828. PMID 24586407 DOI: 10.1371/Journal.Pone.0088828  0.547
2014 Shtraizent N, Shi M, Polotskaya A, Matsui H, Bargonetti J. Abstract 4740: Real-time impedance analysis of triple negative breast cancer cells from African Americans demonstrates oncogenic mutant p53 (mtp53) is a promoter of cellular deformability Cancer Research. 74: 4740-4740. DOI: 10.1158/1538-7445.Am2014-4740  0.498
2014 Rosso M, Polotskaia A, Bargonetti J. Abstract 468: Cancer cells with G/G mdm2 SNP309 have compromised transcriptional elongation of p53 target genes Cancer Research. 74: 468-468. DOI: 10.1158/1538-7445.Am2014-468  0.59
2013 Okoro DR, Arva N, Gao C, Polotskaia A, Puente C, Rosso M, Bargonetti J. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator. Plos One. 8: e77643. PMID 24147044 DOI: 10.1371/Journal.Pone.0077643  0.73
2013 Okoro D, Gao C, Puente C, Polotskaia A, Arva N, Rosso M, Bargonetti J. Abstract 1909: Multiple Mdm2 isoforms promote tumorigenesis, disrupt mammary tissue architecture, and are endogenously expressed in cancers. Cancer Research. 73: 1909-1909. DOI: 10.1158/1538-7445.Am2013-1909  0.769
2012 Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, Avantaggiati ML. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (Georgetown, Tex.). 11: 4436-46. PMID 23151455 DOI: 10.4161/Cc.22778  0.481
2012 Okoro DR, Rosso M, Bargonetti J. Splicing up mdm2 for cancer proteome diversity. Genes & Cancer. 3: 311-9. PMID 23150764 DOI: 10.1177/1947601912455323  0.5
2012 Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J. 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Molecular Cancer Therapeutics. 11: 2495-504. PMID 22973058 DOI: 10.1158/1535-7163.Mct-12-0085  0.594
2012 Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, ... ... Bargonetti J, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148: 244-58. PMID 22265415 DOI: 10.1016/J.Cell.2011.12.017  0.804
2012 Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. Correction: A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation Breast Cancer Research. 14. DOI: 10.1186/Bcr3130  0.796
2012 Bargonetti J, Okoro D, Kundu N, Brekman A, Gao C, Rosso M, Polotskaia A. Abstract 1169: Non-canonical functions of Mdm2 isoforms in estrogen influenced breast cancer cells with wild-type or mutant p53 Cancer Research. 72: 1169-1169. DOI: 10.1158/1538-7445.Am2012-1169  0.547
2011 Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Research : Bcr. 13: R3. PMID 21223569 DOI: 10.1186/Bcr2804  0.816
2011 Polotskaia A, Bargonetti J. Abstract C30: p53-independent 8-amino-adenosine mediated breast cancer cell death Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C30  0.575
2010 Bargonetti J, Champeil E, Tomasz M. Differential toxicity of DNA adducts of mitomycin C. Journal of Nucleic Acids. 2010. PMID 20798760 DOI: 10.4061/2010/698960  0.551
2010 Boamah EK, Brekman A, Tomasz M, Myeku N, Figueiredo-Pereira M, Hunter S, Meyer J, Bhosle RC, Bargonetti J. DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1. Chemical Research in Toxicology. 23: 1151-62. PMID 20536192 DOI: 10.1021/Tx900420K  0.812
2010 Polotskaia A, Brekman A, Bargonetti J. Abstract 838: Mdm2 and oncogenic mutant p53 as biomarkers for potential drug targets in estrogen receptor positive and triple negative breast cancer Cancer Research. 70: 838-838. DOI: 10.1158/1538-7445.Am10-838  0.841
2009 Brekman A, Talbott K, Bargonetti J. p53 transcriptional activity is selectively suppressed by estrogen in SNP309 mdm2 overexpressing breast cancer cells. Cancer Research. 69: 4065. DOI: 10.1158/0008-5472.Sabcs-4065  0.597
2008 Paz MM, Ladwa S, Champeil E, Liu Y, Rockwell S, Boamah EK, Bargonetti J, Callahan J, Roach J, Tomasz M. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography/ electrospray tandem mass spectrometry. Chemical Research in Toxicology. 21: 2370-8. PMID 19053323 DOI: 10.1021/Tx8002615  0.814
2008 Arva NC, Talbott KE, Okoro DR, Brekman A, Qiu WG, Bargonetti J. Disruption of the p53-Mdm2 complex by nutlin-3 reveals different cancer cell phenotypes Ethnicity and Disease. 18: S2-1-S2-8. PMID 18646312  0.838
2008 Bargonetti J, Polotskaia A, Wang S. 201 POSTER In Mdm2 SNP309 cancer cells the small molecules nutlin-3 and MI-63 facilitate recruitment of RNA polymerase II to p53 target genes European Journal of Cancer Supplements. 6: 63-64. DOI: 10.1016/S1359-6349(08)72133-5  0.301
2007 Boamah EK, White DE, Talbott KE, Arva NC, Berman D, Tomasz M, Bargonetti J. Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways. Acs Chemical Biology. 2: 399-407. PMID 17530733 DOI: 10.1021/Cb700060T  0.833
2006 Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 25: 7305-10. PMID 16785993 DOI: 10.1038/Sj.Onc.1209735  0.578
2006 White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Research. 66: 3463-70. PMID 16585169 DOI: 10.1158/0008-5472.Can-05-1381  0.778
2005 Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. The Journal of Biological Chemistry. 280: 26776-87. PMID 15908423 DOI: 10.1074/Jbc.M505203200  0.795
2004 Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119: 591-602. PMID 15550242 DOI: 10.1016/J.Cell.2004.11.022  0.727
2004 Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA. Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53. Molecular and Cellular Biology. 24: 5677-86. PMID 15199126 DOI: 10.1128/Mcb.24.13.5677-5686.2004  0.764
2004 Abbas T, White D, Hui L, Yoshida K, Foster DA, Bargonetti J. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. The Journal of Biological Chemistry. 279: 9970-7. PMID 14699137 DOI: 10.1074/Jbc.M306979200  0.775
2003 Molina MP, Cain C, Bargonetti J. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. Methods in Molecular Biology (Clifton, N.J.). 234: 151-70. PMID 12824531 DOI: 10.1385/1-59259-408-5:151  0.563
2002 Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. The Journal of Biological Chemistry. 277: 40513-9. PMID 12183457 DOI: 10.1074/Jbc.M205495200  0.826
2002 Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Current Opinion in Oncology. 14: 86-91. PMID 11790986 DOI: 10.1097/00001622-200201000-00015  0.472
2001 Houser S, Koshlatyi S, Lu T, Gopen T, Bargonetti J. Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochemical and Biophysical Research Communications. 289: 998-1009. PMID 11741290 DOI: 10.1006/Bbrc.2001.6073  0.787
2000 Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochemical and Biophysical Research Communications. 279: 383-90. PMID 11118296 DOI: 10.1006/Bbrc.2000.3965  0.795
2000 Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. A DNA damage signal is required for p53 to activate gadd45. Cancer Research. 60: 1711-9. PMID 10749144  0.846
1999 Boydston-White S, Gopen T, Houser S, Bargonetti J, Diem M. Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. Biospectroscopy. 5: 219-27. PMID 10478952 DOI: 10.1002/(Sici)1520-6343(1999)5:4<219::Aid-Bspy2>3.0.Co;2-O  0.742
1998 Xiao G, White D, Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene. 16: 1171-81. PMID 9528859 DOI: 10.1038/Sj.Onc.1201631  0.714
1997 Bargonetti J, Chicas A, White D, Prives C. p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cellular and Molecular Biology (Noisy-Le-Grand, France). 43: 935-49. PMID 9449526  0.768
1995 Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), Induces Cyclin D1 Synthesis Cancer Research. 55: 4257-4263. PMID 7671232  0.461
1994 Prives C, Bargonetti J, Farmer G, Ferrari E, Friedlander P, Wang Y, Jayaraman L, Pavletich N, Hubscher U. DNA-binding properties of the p53 tumor suppressor protein Cold Spring Harbor Symposia On Quantitative Biology. 59: 207-213. PMID 7587071 DOI: 10.1101/Sqb.1994.059.01.025  0.458
1993 Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA Proceedings of the National Academy of Sciences of the United States of America. 90: 3319-3323. PMID 8475074 DOI: 10.1073/Pnas.90.8.3319  0.532
1993 Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein Genes and Development. 7: 2565-2574. PMID 8276239 DOI: 10.1101/Gad.7.12B.2565  0.474
1993 Bargonetti J, Wang PZ, Novick RP. Measurement of gene expression by translational coupling: Effect of copy mutations on pT181 initiator synthesis Embo Journal. 12: 3659-3667. PMID 8253088 DOI: 10.1002/J.1460-2075.1993.Tb06040.X  0.312
1993 Bargonetti J, Wang P, Novick R. Measurement of gene expression by translational coupling: effect of copy mutations on pT181 initiator synthesis. The Embo Journal. 12: 3659-3667. DOI: 10.1002/j.1460-2075.1993.tb06040.x  0.394
1992 Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element Genes and Development. 6: 1143-1152. PMID 1628822 DOI: 10.1101/Gad.6.7.1143  0.505
1992 Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature. 358: 83-6. PMID 1614538 DOI: 10.1038/358083A0  0.527
1992 Bargonetti J, Reynisdottir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 Genes and Development. 6: 1886-1898. PMID 1398068 DOI: 10.1101/Gad.6.10.1886  0.484
1991 Prives C, Bargonetti J, Friedman PN, Manfredi JJ, Wang EH. Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen Cold Spring Harbor Symposia On Quantitative Biology. 56: 227-235. PMID 1668081 DOI: 10.1101/Sqb.1991.056.01.028  0.34
1991 Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication Cell. 65: 1083-1091. PMID 1646078 DOI: 10.1016/0092-8674(91)90560-L  0.507
1990 Noirot P, Bargonetti J, Novick RP. Initiation of rolling-circle replication in pT181 plasmid: Initiator protein enhances cruciform extrusion at the origin Proceedings of the National Academy of Sciences of the United States of America. 87: 8560-8564. PMID 2236066 DOI: 10.1073/Pnas.87.21.8560  0.544
Show low-probability matches.